WuXi AppTec (WUXAY) Stock Price, News & Analysis

Company Overview

WuXi AppTec is a global contract research, development and manufacturing organization (CDMO) providing services to pharmaceutical, biotechnology and medical device companies. Founded in 2000 and headquartered in Shanghai, the company offers a broad portfolio of R&D and manufacturing solutions covering small molecules, biologics, cell and gene therapies, medical device testing and genomics services. Its integrated platform supports drug discovery through clinical trials and commercial manufacturing, enabling clients to accelerate the development of novel therapeutics.

On the discovery side, WuXi AppTec delivers capabilities in medicinal chemistry, biology, pharmacology, drug metabolism and pharmacokinetics (DMPK), and bioanalytics. In addition to early-stage research, the company provides comprehensive preclinical safety assessments, GLP-compliant toxicology studies and regulatory support. For clinical development and commercial supply, WuXi AppTec’s GMP facilities include small-molecule drug substance manufacturing, biologics process development and GMP biologics production, as well as cell and gene therapy contract manufacturing.

Operating through more than 20 facilities across China, the United States, Europe and other regions, WuXi AppTec serves a diverse global client base ranging from emerging biotech firms to multinational pharmaceutical companies. The company’s geographically distributed network of laboratories and manufacturing sites is designed to meet local regulatory requirements while leveraging global expertise to accelerate project timelines and optimize development costs.

WuXi AppTec was founded by Dr. Ge Li, who serves as chairman, and the company’s executive leadership is led by president and CEO Dr. Chris X. Ding. Under their guidance, WuXi AppTec has expanded its service offerings and geographic footprint to address the evolving needs of the life sciences industry, with a focus on enabling scientific innovation and improving patient access to new therapies.

Key Stats

• Today's Range: $13.40 to $13.72
• 50-Day Range: $9.26 to $14.24
• 52-Week Range: $4.06 to $15.10
• Volume: 443 shs
• Average Volume: 7,289 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

WUXAY Stock Analysis - Frequently Asked Questions

How have WUXAY shares performed this year?

WuXi AppTec's stock was trading at $7.20 on January 1st, 2025. Since then, WUXAY shares have increased by 86.1% and is now trading at $13.40.

How do I buy shares of WuXi AppTec?

Shares of WUXAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 8/17/2025
• Next Earnings (Estimated): 10/27/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:WUXAY
• CIK: N/A
• Web: www.wuxiapptec.com
• Phone: 862120663091
• Fax: N/A
• Employees: 41,116
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A